RESEARCH STARTER

Bioethics of genetics

The bioethics of genetics explores the ethical implications arising from advancements in genetic research, testing, and therapies. It addresses critical issues such as informed consent, the rights of patients, and the potential for discrimination based on genetic information. As genetic testing becomes more accessible, individuals face complex decisions about whether to undergo testing, particularly when the knowledge gained may not lead to actionable outcomes or may carry social stigma. Bioethicists play a pivotal role in guiding these decisions, helping to navigate the risks and benefits of genetic information, especially in vulnerable populations.

The emergence of policies, such as the Genetic Information Nondiscrimination Act (GINA), reflects ongoing efforts to protect individuals from potential discrimination based on their genetic data. Furthermore, ongoing research, including genome-wide association studies, poses questions about the interpretation of genetic information and its implications for health management. As genetic sequencing technology continues to evolve and costs decrease, the ethical debate intensifies around the responsibilities of individuals and healthcare providers in utilizing such information. Overall, the field of genetic bioethics emphasizes the need for respectful consideration of diverse perspectives and societal impacts as genetic technologies advance.

Full Article

SIGNIFICANCE: Bioethics is a branch of philosophy concerned with the ethical implications of advances in biology and medicine. It is the practice of helping societies draw lines, often through politics and law, around what is acceptable and appropriate in biological research and medical practice as they relate to human health and well-being. With regard to genetics, bioethics deals with issues such as the pros and cons of genetic testing.

The Emergence of Bioethics

As early as the mid-1960s, advances in genetics and reproduction, life support, and transplantation technologies spurred an increased focus on ethical issues in medicine and scientific research, or bioethics. From the late 1960s through the mid-1970s, bioethicists were preoccupied with the moral difficulties of obtaining voluntary, informed consent from human subjects in scientific research. They concentrated on the development of ethical guidelines in research that would ensure the protection of individuals vulnerable to exploitation, including individuals with mental or physical disabilities, incarcerated individuals, and children. Beginning in the mid-1970s and continuing through the mid-1980s, bioethicists became increasingly involved in discussions of the definitions of life, death, and what it means to be human. In the mid-1980s, practitioners began focusing on cost containment in healthcare and the allocation of scarce medical resources.

Beginning in 1992, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO, now simply the Joint Commission), the US agency that accredits hospitals and healthcare institutions, required these organizations to establish committees to formulate ethics policies and address issues around medical ethics. Ethics teams within hospitals and professional organizations exist to provide consultation regarding ethical dilemmas in clinical practice and research. Such resources are critical, as technological advances, particularly related to genetics and genomics, proceed more rapidly than policy. Organizations for the study of biomedical ethics, such as the American Society for Bioethics and Humanities, are important forums for public debate and research. Following the completion of the Human Genome Project in 2003, many organizations committed to ethical research and policy making related to the use of genomic information.

The overriding principle of bioethics and US law is to respect each person’s right to make decisions, free of coercion, about treatments or procedures they will undergo. This principle is complicated when the person making the decision is considered incompetent because of youth, intellectual disability, or medical deterioration. Other important principles include a patient’s right to know that medical practitioners are telling the truth, the right to know the risks and benefits of proposed medical treatment, and the right to privacy of health information.

Impact and Applications

Advances in genomics and genetic testing have presented numerous dilemmas for bioethicists, patients, and healthcare providers. For example, as the ability to forecast and understand the genetic code progresses, people will have to decide whether knowing the future, even if it cannot be altered or changed, is beneficial to them or their children. Knowledge of the genomic basis of common diseases has led to the birth of direct-to-consumer marketing of testing that provides individuals with often complicated risk profiles for conditions such as diabetes and heart disease. Bioethicists are critical players in policy-making regarding this form of personalized medicine.

Bioethicists help people determine the value of genetic testing, including the risks and benefits of genetic testing in particular situations. Factors typically considered before a person undergoes genetic testing include the nature of the test, the timing of the test, and the impact that the results will have on health and medical management. Testing can be done prenatally to detect disorders in fetuses; it can also be done before conception to determine whether a prospective parent is a carrier for a particular disorder or disease that could be passed to a child. Technology even allows for testing of embryos created by in vitro fertilization, thereby preventing the transmission of a genetic condition by transferring only unaffected embryos to the mother’s womb. Predictive and presymptomatic genetic tests can provide information about whether an adult has an increased susceptibility to, or will ultimately manifest symptoms of, a genetic disorder. Information gained from genetic testing could help predict the nature and severity of a particular disorder as well as potential options for screening or intervention. Knowing one’s genetic fate may be more of a burden than a person wants, however, particularly if nothing can be done to change or alter the risks that the person faces. Bioethicists act as guides through the complicated and often wrenching decision process.

Consumers of genetic testing must also decide whether the knowledge gained from the test is worth potential legal and social implications. In 2008, the Genetic Information Nondiscrimination Act (GINA) was signed into law. GINA provides protection against genetic discrimination in health insurance and employment, but it does not protect other insurance arenas, such as life insurance and disability insurance. Fear of discrimination may prevent some individuals from pursuing genetic testing that could provide beneficial guidance for preventive care. For example, a woman with a strong family history of breast cancer could have genetic testing to determine if she has inherited a hereditary cancer predisposition syndrome, which, in turn, would lead to increased vigilance with breast screening. Many women in this situation defer testing because of discrimination fears, risking detection of cancer at a much later stage, with potentially devastating consequences. Bioethicists can help guide policymakers in creating stricter protections against potential discrimination. In 2026, Australia passed legislation banning life insurers from using adverse genetic testing results to deny or limit life insurance coverage, reflecting broader international concern over genetic discrimination.

The Human Genome Project provided researchers with a wealth of information, but this comes with a paucity of knowledge about the specific effects of the genetic sequence related to health and disease. Genome-wide association studies are ongoing to better understand the complicated nature of gene-gene and gene-environment interactions. In 2007, the first individual genome was sequenced, that of biologist Craig Venter, and the cost for individuals to sequence their own genomes fell significantly, from about $14 million in 2006 to under $1,000 in the 2020s. As this price continued dropping and more healthy people could have access to whole-genome sequencing, debates continued over the ethical pros and cons of accessing this information without an immediate medical purpose. As genomic tools and tests became more widely available, concerns grew about unequal access among marginalized communities. Bioethicists have stressed the importance of inclusive genomic research and the equitable distribution of personalized medicine. The rise of artificial intelligence in healthcare also generated ethical concerns regarding the transparency of algorithmic decisions, potential biases in training data, and patient autonomy. In 2024, the World Health Organization issued principles for ethical human genomic data collection, access, use, and sharing, emphasizing protection of individual rights, equity, and responsible international collaboration.

Some critics expressed concern that a healthy person who sequences their genome may take unnecessary steps to avoid potential medical ailments based on the analysis without properly understanding the reading or that such an analysis could give someone a false sense of invincibility for certain diseases. Therefore, the challenge to bioethicists, researchers, and the general public is how to interpret the information in a meaningful way and protect individuals’ privacy as more information is potentially disseminated.

The development of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-based gene editing opened new ethical concerns about whether future generations may inherit changes made to DNA. While non-heritable gene editing for treatment purposes was generally accepted under ethical review, heritable genome editing raises profound concerns about consent, equity, and long-term consequences. In December 2023, the FDA approved Casgevy for sickle cell disease, making it the first FDA-approved therapy to use CRISPR/Cas9 genome editing; in January 2024, the approval was expanded to transfusion-dependent beta-thalassemia. As medicine becomes increasingly personalized and data-driven, bioethicists play a key role in ensuring that innovation aligns with justice, transparency, and respect for persons.

Key Terms

  • genetic testing: the use of the techniques of genetics research to determine a person’s risk of developing, or status as a carrier of, a disease or other disorder
  • informed consent: the right of patients to know the risks of medical treatment and to determine what is done to their bodies

Bibliography

Beauchamp, Tom, et al. Contemporary Issues in Bioethics. 8th ed., Thomson/Wadsworth, 2014.

Brothers, Kyle B., and Ellen W. Clayton. “Bioethics of Genetic and Genomic Testing.” Encyclopedia of Life Sciences, 20 Mar. 2017, doi:10.1002/9780470015902.a0003478.pub2. Accessed 16 May 2026.

Bulger, Ruth Ellen, et al., editors. The Ethical Dimensions of the Biological and Health Sciences. 2nd ed., Cambridge UP, 2002.

Cambra-Badii, Irene, et al. Bioethics: Foundations, Applications and Future Challenges. CRC Press, 2024.

Caplan, Arthur. Due Consideration: Controversy in the Age of Medical Miracles. Wiley, 1997.

Chadwick, Ruth F., et al. The Right to Know and the Right Not to Know: Genetic Privacy and Responsibility. Cambridge UP, 2014.

“The Cost of Sequencing a Human Genome.” National Human Genome Research Institute, 1 Nov. 2021, www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost. Accessed 16 May 2026.

Di Nucci, Ezio, et al. The Rowman & Littlefield Handbook of Bioethics. Rowman & Littlefield, 2023.

Evans, John Hyde. Playing God? Human Genetic Engineering and the Rationalization of Public Bioethical Debate. U of Chicago P, 2002.

“FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease.” U.S. Food and Drug Administration, 8 Dec. 2023, www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease. Accessed 16 May 2026.

Kruse, Judith, et al. “Genetic Testing for Rare Diseases: A Systematic Review of Ethical Aspects.” Frontiers in Genetics, vol. 12, 2021, p. 701988, doi:10.3389/fgene.2021.701988. Accessed 16 May 2026.

Mepham, Ben. Bioethics: An Introduction for the Biosciences. Oxford UP, 2008.

Mulino, Daniel. “Legislation Passed to Ban the Use of Adverse Genetic Testing Results in Life Insurance.” Treasury Ministers, Australian Government, 1 Apr. 2026, ministers.treasury.gov.au/ministers/daniel-mulino-2025/media-releases/legislation-passed-ban-use-adverse-genetic-testing. Accessed 16 May 2026.

Sandler, Ronald L., and John Basl. Designer Biology: The Ethics of Intensively Engineering Biological and Ecological Systems. Lexington, 2013.

Schüklenk, Udo, and Peter Singer. Bioethics: An Anthology. 4th ed., John Wiley & Sons, 2022.

Tamparo, Carol D., and Marcia A. Lewis. Medical Law, Ethics, & Bioethics for the Health Professions. 8th ed., F. A. Davis Company, 2022.

Tirrell, Meg. “Unlocking My Genome: Was It Worth It?” CNBC, 10 Dec. 2015, www.cnbc.com/2015/12/10/unlocking-my-genome-was-it-worth-it.html. Accessed 16 May 2026.

“WHO Releases New Principles for Ethical Human Genomic Data Collection and Sharing.” World Health Organization, 20 Nov. 2024, www.who.int/news/item/20-11-2024-who-releases-new-principles-for-ethical-human-genomic-data-collection-and-sharing. Accessed 16 May 2026.

Full Article

SIGNIFICANCE: Bioethics is a branch of philosophy concerned with the ethical implications of advances in biology and medicine. It is the practice of helping societies draw lines, often through politics and law, around what is acceptable and appropriate in biological research and medical practice as they relate to human health and well-being. With regard to genetics, bioethics deals with issues such as the pros and cons of genetic testing.

The Emergence of Bioethics

As early as the mid-1960s, advances in genetics and reproduction, life support, and transplantation technologies spurred an increased focus on ethical issues in medicine and scientific research, or bioethics. From the late 1960s through the mid-1970s, bioethicists were preoccupied with the moral difficulties of obtaining voluntary, informed consent from human subjects in scientific research. They concentrated on the development of ethical guidelines in research that would ensure the protection of individuals vulnerable to exploitation, including individuals with mental or physical disabilities, incarcerated individuals, and children. Beginning in the mid-1970s and continuing through the mid-1980s, bioethicists became increasingly involved in discussions of the definitions of life, death, and what it means to be human. In the mid-1980s, practitioners began focusing on cost containment in healthcare and the allocation of scarce medical resources.

Beginning in 1992, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO, now simply the Joint Commission), the US agency that accredits hospitals and healthcare institutions, required these organizations to establish committees to formulate ethics policies and address issues around medical ethics. Ethics teams within hospitals and professional organizations exist to provide consultation regarding ethical dilemmas in clinical practice and research. Such resources are critical, as technological advances, particularly related to genetics and genomics, proceed more rapidly than policy. Organizations for the study of biomedical ethics, such as the American Society for Bioethics and Humanities, are important forums for public debate and research. Following the completion of the Human Genome Project in 2003, many organizations committed to ethical research and policy making related to the use of genomic information.

The overriding principle of bioethics and US law is to respect each person’s right to make decisions, free of coercion, about treatments or procedures they will undergo. This principle is complicated when the person making the decision is considered incompetent because of youth, intellectual disability, or medical deterioration. Other important principles include a patient’s right to know that medical practitioners are telling the truth, the right to know the risks and benefits of proposed medical treatment, and the right to privacy of health information.

Impact and Applications

Advances in genomics and genetic testing have presented numerous dilemmas for bioethicists, patients, and healthcare providers. For example, as the ability to forecast and understand the genetic code progresses, people will have to decide whether knowing the future, even if it cannot be altered or changed, is beneficial to them or their children. Knowledge of the genomic basis of common diseases has led to the birth of direct-to-consumer marketing of testing that provides individuals with often complicated risk profiles for conditions such as diabetes and heart disease. Bioethicists are critical players in policy-making regarding this form of personalized medicine.

Bioethicists help people determine the value of genetic testing, including the risks and benefits of genetic testing in particular situations. Factors typically considered before a person undergoes genetic testing include the nature of the test, the timing of the test, and the impact that the results will have on health and medical management. Testing can be done prenatally to detect disorders in fetuses; it can also be done before conception to determine whether a prospective parent is a carrier for a particular disorder or disease that could be passed to a child. Technology even allows for testing of embryos created by in vitro fertilization, thereby preventing the transmission of a genetic condition by transferring only unaffected embryos to the mother’s womb. Predictive and presymptomatic genetic tests can provide information about whether an adult has an increased susceptibility to, or will ultimately manifest symptoms of, a genetic disorder. Information gained from genetic testing could help predict the nature and severity of a particular disorder as well as potential options for screening or intervention. Knowing one’s genetic fate may be more of a burden than a person wants, however, particularly if nothing can be done to change or alter the risks that the person faces. Bioethicists act as guides through the complicated and often wrenching decision process.

Consumers of genetic testing must also decide whether the knowledge gained from the test is worth potential legal and social implications. In 2008, the Genetic Information Nondiscrimination Act (GINA) was signed into law. GINA provides protection against genetic discrimination in health insurance and employment, but it does not protect other insurance arenas, such as life insurance and disability insurance. Fear of discrimination may prevent some individuals from pursuing genetic testing that could provide beneficial guidance for preventive care. For example, a woman with a strong family history of breast cancer could have genetic testing to determine if she has inherited a hereditary cancer predisposition syndrome, which, in turn, would lead to increased vigilance with breast screening. Many women in this situation defer testing because of discrimination fears, risking detection of cancer at a much later stage, with potentially devastating consequences. Bioethicists can help guide policymakers in creating stricter protections against potential discrimination. In 2026, Australia passed legislation banning life insurers from using adverse genetic testing results to deny or limit life insurance coverage, reflecting broader international concern over genetic discrimination.

The Human Genome Project provided researchers with a wealth of information, but this comes with a paucity of knowledge about the specific effects of the genetic sequence related to health and disease. Genome-wide association studies are ongoing to better understand the complicated nature of gene-gene and gene-environment interactions. In 2007, the first individual genome was sequenced, that of biologist Craig Venter, and the cost for individuals to sequence their own genomes fell significantly, from about $14 million in 2006 to under $1,000 in the 2020s. As this price continued dropping and more healthy people could have access to whole-genome sequencing, debates continued over the ethical pros and cons of accessing this information without an immediate medical purpose. As genomic tools and tests became more widely available, concerns grew about unequal access among marginalized communities. Bioethicists have stressed the importance of inclusive genomic research and the equitable distribution of personalized medicine. The rise of artificial intelligence in healthcare also generated ethical concerns regarding the transparency of algorithmic decisions, potential biases in training data, and patient autonomy. In 2024, the World Health Organization issued principles for ethical human genomic data collection, access, use, and sharing, emphasizing protection of individual rights, equity, and responsible international collaboration.

Some critics expressed concern that a healthy person who sequences their genome may take unnecessary steps to avoid potential medical ailments based on the analysis without properly understanding the reading or that such an analysis could give someone a false sense of invincibility for certain diseases. Therefore, the challenge to bioethicists, researchers, and the general public is how to interpret the information in a meaningful way and protect individuals’ privacy as more information is potentially disseminated.

The development of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-based gene editing opened new ethical concerns about whether future generations may inherit changes made to DNA. While non-heritable gene editing for treatment purposes was generally accepted under ethical review, heritable genome editing raises profound concerns about consent, equity, and long-term consequences. In December 2023, the FDA approved Casgevy for sickle cell disease, making it the first FDA-approved therapy to use CRISPR/Cas9 genome editing; in January 2024, the approval was expanded to transfusion-dependent beta-thalassemia. As medicine becomes increasingly personalized and data-driven, bioethicists play a key role in ensuring that innovation aligns with justice, transparency, and respect for persons.

Key Terms

  • genetic testing: the use of the techniques of genetics research to determine a person’s risk of developing, or status as a carrier of, a disease or other disorder
  • informed consent: the right of patients to know the risks of medical treatment and to determine what is done to their bodies

Bibliography

Beauchamp, Tom, et al. Contemporary Issues in Bioethics. 8th ed., Thomson/Wadsworth, 2014.

Brothers, Kyle B., and Ellen W. Clayton. “Bioethics of Genetic and Genomic Testing.” Encyclopedia of Life Sciences, 20 Mar. 2017, doi:10.1002/9780470015902.a0003478.pub2. Accessed 16 May 2026.

Bulger, Ruth Ellen, et al., editors. The Ethical Dimensions of the Biological and Health Sciences. 2nd ed., Cambridge UP, 2002.

Cambra-Badii, Irene, et al. Bioethics: Foundations, Applications and Future Challenges. CRC Press, 2024.

Caplan, Arthur. Due Consideration: Controversy in the Age of Medical Miracles. Wiley, 1997.

Chadwick, Ruth F., et al. The Right to Know and the Right Not to Know: Genetic Privacy and Responsibility. Cambridge UP, 2014.

“The Cost of Sequencing a Human Genome.” National Human Genome Research Institute, 1 Nov. 2021, www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost. Accessed 16 May 2026.

Di Nucci, Ezio, et al. The Rowman & Littlefield Handbook of Bioethics. Rowman & Littlefield, 2023.

Evans, John Hyde. Playing God? Human Genetic Engineering and the Rationalization of Public Bioethical Debate. U of Chicago P, 2002.

“FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease.” U.S. Food and Drug Administration, 8 Dec. 2023, www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease. Accessed 16 May 2026.

Kruse, Judith, et al. “Genetic Testing for Rare Diseases: A Systematic Review of Ethical Aspects.” Frontiers in Genetics, vol. 12, 2021, p. 701988, doi:10.3389/fgene.2021.701988. Accessed 16 May 2026.

Mepham, Ben. Bioethics: An Introduction for the Biosciences. Oxford UP, 2008.

Mulino, Daniel. “Legislation Passed to Ban the Use of Adverse Genetic Testing Results in Life Insurance.” Treasury Ministers, Australian Government, 1 Apr. 2026, ministers.treasury.gov.au/ministers/daniel-mulino-2025/media-releases/legislation-passed-ban-use-adverse-genetic-testing. Accessed 16 May 2026.

Sandler, Ronald L., and John Basl. Designer Biology: The Ethics of Intensively Engineering Biological and Ecological Systems. Lexington, 2013.

Schüklenk, Udo, and Peter Singer. Bioethics: An Anthology. 4th ed., John Wiley & Sons, 2022.

Tamparo, Carol D., and Marcia A. Lewis. Medical Law, Ethics, & Bioethics for the Health Professions. 8th ed., F. A. Davis Company, 2022.

Tirrell, Meg. “Unlocking My Genome: Was It Worth It?” CNBC, 10 Dec. 2015, www.cnbc.com/2015/12/10/unlocking-my-genome-was-it-worth-it.html. Accessed 16 May 2026.

“WHO Releases New Principles for Ethical Human Genomic Data Collection and Sharing.” World Health Organization, 20 Nov. 2024, www.who.int/news/item/20-11-2024-who-releases-new-principles-for-ethical-human-genomic-data-collection-and-sharing. Accessed 16 May 2026.

More Like ThisRelated Articles

Related Articles (4)

Related Articles (4)